HIV and cytomegalovirus in Thailand. by Chua, A et al.
Mahar Ghandi and Rajiv Khanna’s recent review of
cytomegalovirus infection highlights the important
burden of this disease in immunocompromised
individuals.1 In Thailand, where ophthalmological
changes due to cytomegalovirus have been observed in a
third of HIV-infected patients,2 management of
cytomegalovirus retinitis poses a considerable challenge.
Treatment of opportunistic infections is an integral
part of HIV management. Local production of generic
HIV medicines3 in Thailand is making treatment more
affordable. For example, 4 years ago treatment of
cryptococcal meningitis was out of reach for most
because ﬂuconazole cost US$13 a day. Generic
production reduced the cost to 30 cents a day and this
treatment is now universally available. 
Ideally, treatment of cytomegalovirus retinitis requires
both intravenous therapy and intravitreal ganciclovir
injections, both of which are costly and impractical.
Intravitreal injections require referral to an
ophthalmologist at provincial level, although in practice
few ophthalmologists provide this service. Long-term
intravenous therapy is difﬁcult to administer. 
Of 228 adults receiving highly active antiretroviral
therapy in three district hospitals where we work,4
cytomegalovirus retinitis was conﬁrmed in 12 severely
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100 000 years ago,12 at least 100 million years after
Gondwana had broken into the continents we know
today. M ulcerans is thus of relatively recent evolution
and the infection it causes does not belong to the
Jurassic period.
An explanation is still required as to how the same, or
essentially similar, immotile organism may be in distinct,
deﬁned, separate loci in three different continents as
well as in other apparently isolated locations. Infected
insects may represent a local ampliﬁcation mechanism
or a secondary cycle within the aquatic environment,
but their infection by itself cannot explain the
intercontinental spread of the disease.
Wild ducks (genus Anas; ﬁgure) have been implicated
in occasional, isolated infections in Australian patients.
Ducks ingest aquatic plants and insects, and
mycobacteria have been shown to survive transit in
animal intestines. Ducks are ubiquitous, migrate
between continents, and defaecate on water. Instead of
drifting on the surface of separating continents over the
millennia, M ulcerans may well have ﬂown—economy
class with stopovers—on its way to establish new foci of
infection, ﬂying in the gut of a bird. 
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Intervention Outcome
Intravitreal ganciclovir + HAART (n=5) Four people retained useful vision
One patient became blind and later died
Intravenous ganciclovir for 2 weeks + HAART (n=1) Patient retained useful vision
HAART only. No cytomegalovirus treatment (n=6) Two patients retained useful vision 
One patient was already blind at initiation of HAART and 
later died
Three patients became blind and later died (in two cases, 
after discontinuing HAART)
HAART=highly active antiretroviral therapy
Table: Treatment access for patients with cytomegalovirus in three district hospitals in Thailand
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immunocompromised patients (table). Those people
who received ganciclovir treatment—either intravitreal
or intravenous injection, but never both—generally
responded well. However, half of the patients were too
sick to travel to the referral hospital and therefore
received no treatment.
The reality in Thailand is that many cytomegalovirus
patients remain untreated. Ganciclovir is a monopoly
product and intravenous treatment remains
prohibitively expensive, costing US$465 per week.
Valganciclovir, which is administered orally, would be
highly desirable for use in resource-poor settings, but
costs US$840 per week, must be administered for many
months, and is not registered in Thailand. 
For now, an evaluation of the cost-beneﬁt and feasibility
of wider provision of intravitreal ganciclovir injections
needs to be undertaken, even though this is considered to
be a suboptimal treatment. Future medicines, such as
maribavir, are likely to be as irrelevant to Thailand and
other developing countries as valganciclovir unless
equitable pricing policies are implemented.
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Well they all are, I suppose. But what the article on 
page 345 by David Huang and Herbert DuPont does 
is review a clinical problem—extra-intestinal compli-
cations of typhoid fever—for which there is a paucity of
evidence on treatment from randomised trials. This
review is the ﬁrst in an occasional “Problem pathogen”
series, which will have as its theme reasonably common
infectious conditions whose therapy is uncertain or
controversial because of a lack of randomised treatment
trials. For coming up with the idea for the series, and for
doing much of the leg work of commissioning authors, I
thank Victor Yu, University of Pittsburgh, PA, USA. In
the words of Professor Yu when he ﬁrst suggested the
series, we hope that these will be decision-facilitating
articles for clinicians everywhere.
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